SCHEMBL1820040

SCHEMBL1820040

CC(=O)c1csc(Br)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27682287 0.81 CES2 (0.39)
SCHEMBL568600 0.79
SCHEMBL1674356 0.77
SCHEMBL2181763 0.77
Hydrochloric Acid SCHEMBL9626058 0.77 DAO (0.54)
SCHEMBL1750114 0.77 HDAC8 (0.45)
SCHEMBL25819048 0.77 GSK3B (0.40)
SCHEMBL365156 0.77 CA1 (0.45)
SCHEMBL3094449 0.76
SCHEMBL3094452 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 US disclosed
US-12552757-B2 NRF2-activating compound SENJU PHARMACEUTICAL CO., LTD. (JP) 2026-02-17 US disclosed
US-20240132519-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2024-04-25 US disclosed
EP-4273145-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2023-11-08 EP disclosed
EP-4273145-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2023-11-08 EP disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed
CN-116669744-A Nrf2 activating compounds 千寿制药株式会社 2023-08-29 CN disclosed
US-20230024995-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-01-26 US disclosed
US-20230024995-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-01-26 US disclosed
US-20220396581-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. (US) 2022-12-15 US disclosed
EP-0610032-A1 Acetanilide derivatives ZENECA LIMITED (GB) 1994-08-10 EP disclosed
US-5332757-A Enzyme inhibitors ZENECA LIMITED (GB) 1994-07-26 US disclosed
EP-0316179-B1 Photochromic compounds TOKUYAMA SODA KK (JP) 1994-01-19 EP disclosed
EP-0555068-A1 Oxime derivatives as 5-lipoxygenase inhibitors ZENECA LIMITED (GB) 1993-08-11 EP disclosed
US-4960678-A FULGIDES, FULGIMIDES AND HIGH MOLECULAR POLYMER; LENSES TOKUYAMA SODA KABUSHIKI KAISHA (JP) 1990-10-02 US disclosed
EP-0140540-B1 PHOTOCHROMIC COMPOUNDS AND THEIR USES IN PHOTOREACTIVE LENSES THE PLESSEY COMPANY plc (GB) 1990-05-09 EP disclosed
US-4882438-A DURABILITY; HETEROCYCLIC IMIDE COMPOUND TOKUYAMA SODA KABUSHIKI KAISHA (JP) 1989-11-21 US disclosed
EP-0316179-A2 Photochromic compounds TOKUYAMA SODA KABUSHIKI KAISHA (JP) 1989-05-17 EP disclosed
US-4685783-A Polychromic tetracyclo-spiro-adamatylidene derivatives, and polychromic lens incorporating said compounds THE PLESSEY COMPANY P.L.C. (GB) 1987-08-11 US disclosed
EP-0140540-A2 Photochromic compounds and their uses in photoreactive lenses THE PLESSEY COMPANY plc (GB) 1985-05-08 EP disclosed